Drugs / GATAPARSEN
GATAPARSEN
also known as
LY2181308 · GATAPARSEN SODIUM · LY-2181308 HEPTADECASODIUM SALT · LY2181308 sodium · sodium LY2181308
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00415155 | Aug 2008 → Jan 2011 | hepatocellular carcinoma | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT01107444 | May 2010 → Dec 2011 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | Missed primary |
| Phase 2 | NCT00642018 | Mar 2008 → Aug 2011 | prostate cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00620321 | Mar 2008 → Jan 2010 | acute myeloid leukemia | Eli Lilly and Company | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2009-06-01 | Ionis Pharmaceuticals | Results Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO ionis.com ↗
In addition, new results from a Phase 1 trial evaluating LY2181308, an antisense drug discovered by Isis and licensed to Eli Lilly and Company, in patients with cancer were also presented. |
| 2008-06-02 | Ionis Pharmaceuticals | Results Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology ionis.com ↗
Lilly presented first-in-human data from LY2181308 that showed the drug distributed to tumor cells with evidence of reduced survivin protein levels in tumor cells, LY2181308's target and one of the most commonly elevated proteins in cancer. |
| 2003-11-20 | Ionis Pharmaceuticals | Results Antisense Drug Targeting Survivin Inhibits Growth Of Tumors In Animal Models ionis.com ↗
Antitumor activity was associated with significant reduction of survivin expression in tumors, evidence that the drug was working through an antisense mechanism. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2009-06-01 | Ionis Pharmaceuticals | Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO ionis.com ↗ |
| 2008-06-02 | Ionis Pharmaceuticals | Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology ionis.com ↗ |
| 2003-11-20 | Ionis Pharmaceuticals | Antisense Drug Targeting Survivin Inhibits Growth Of Tumors In Animal Models ionis.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GATAPARSEN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2219774 ↗ |
| Known as | GATAPARSEN SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2219774 ↗ |
| Known as | LY-2181308 HEPTADECASODIUM SALT | ChEMBL registry synonym — accepted as the source's own label CHEMBL2219774 ↗ |
| Known as | LY2181308 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00415155 ↗ |
| Known as | LY2181308 sodium | “LY2181308 sodium (referred to as LY2181308 throughout this record) administered weekly plus docetaxel 75 mg/m² intravenously administered every 21 days.” NCT00642018 ↗ |
| Known as | sodium LY2181308 | “The antisense oligonucleotide sodium LY2181308 (LY2181308) inhibits survivin expression and may cause cell cycle arrest and restore apoptosis in AML.” PMID 23397500 ↗ Feb 2013 |
| Action | Inhibit | “inhibits survivin expression” PMID 23397500 ↗ Feb 2013 |
| Modality | Antisense oligonucleotide | “Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308” PMID 23397500 ↗ Feb 2013 |
| Route | Intravenous | “250mg, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle.” NCT00415155 ↗ |